Neutral
Pfizer's stock stabilizes at $27.95 after FDA approves new COVID-19 vaccine.
Pfizer's stock remains steady following the FDA's approval of its updated COVID-19 vaccine for the 2026/27 season. The vaccine is authorized for seniors and high-risk individuals, with shipments to U.S. pharmacies, hospitals, and clinics beginning immediately. However, the FDA has revoked the emergency use authorization for Pfizer's COVID-19 vaccine in children under five years old.
Key points
- FDA approves Pfizer's updated COVID-19 vaccine for seniors and high-risk individuals.
- FDA revokes emergency use authorization for Pfizer's COVID-19 vaccine in children under five.
- Pfizer's stock price remains near analyst target of $28.28.
Sources
AI-generated from public news sources. Not financial advice.
